A survival benefit has been observed in patients treated with 223Ra as compared to placebo and 177Lu-DKFZ-617 PSMA has been shown to induce remission in a patient with metastatic prostate cancer (Kratochwil et al2015). The gene discussed is FOLH1; the disease is metastatic prostate carcinoma.